期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HAG方案治疗低增生性老年初发急性髓细胞白血病的疗效分析 被引量：1

暂未订购
导出
摘要 目的探讨低增生性老年初发急性髓细胞白血病(AML)的治疗方法。方法应用HAG预激方案治疗低增生性老年初发AML13例,观察治疗1和2个疗程时的疗效及毒副反应。结果 13例患者经1个疗程化疗后8例获得完全缓解(CR)(61.5%),3例部分缓解(PR)(23.1%),2例未缓解(NR)(15.4%),总有效(ORR)率84.6%。2个疗程治疗后CR率为69.2%,ORR率76.9%。骨髓抑制比常规化疗抑制较轻,未见严重心、肝及肾等重要器官损害。结论 HAG方案治疗低增生性老年初发AML效果较好,化疗耐受性高。
作者 陈幼芬 夏永明 田炳如
机构地区 浙江省余姚市人民医院
出处 《现代实用医学》 2010年第6期690-691,714,共3页 Modern Practical Medicine
关键词 老年人 白血病 粒细胞 急性 抗肿瘤联合化疗方案 粒细胞集落刺激因子
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献7

二级参考文献22

  • 1全国白血病化学治疗讨论会.急性白血病疗效标准[J].中华血液学杂志,1988,9(3):183-183.
  • 2Alessandrino EP, Amadori S, Barosi G, et al. Evidence- and consensus-based practice guidelines for the therapy of myelodysplastic syndromes:a statement from the Italian Society of Hematology. Haematologica,2002;87(12) :1286-1306.
  • 3Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubiein for previously treated acute myelogenous leukemia:a pilot study. Leukemia,1995,9(1):10-14.
  • 4Saito K. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol, 2000;71(3) :238-244.
  • 5Li JM, Shen Y, Wu DP, et al. Aclarubicin and low-dose Cytosine arabinoslde in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients. Int J Hematol,2005 82(1) :48-54.
  • 6Hiddemann W, Martin WR, Sauerland CM,et al. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubiein (TAD 9) in 150 patients with relapse after standardized first line therapy.Leukemia, 1990, 4: 184-188.
  • 7Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aelarubiein for previously treated acute myelngenous leukemia: a pilot study. Leukemia, 1995, 9: 10-14.
  • 8Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML)and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol, 2000. 71: 238-244.
  • 9Park LS, Waldron PE, Friend D, et al. Interleukin-3, GM-CSF and G-CSF receptor expression on cell lines and primary leukemia cells: receptor heterogeneity and relationship to growth factor responsiveness. Blood, 1989, 74: 56-65.
  • 10Wormann B, Reuter C, Zuhlsdorf M, et al. Experimental basis for the use of recombinant human granulocyte-maerophage colonystimulating factor in patients with acute myeloid leukemia. Semin Oncol, 1994, 21(6 suppl 16) : 39-43.

共引文献53

同被引文献4

引证文献1

现代实用医学
2010年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部